Safety of immune checkpoint inhibitors in cancer patients with hepatitis C virus infection
Safety of immune checkpoint inhibitors in cancer patients with hepatitis C virus infection Background The safety of immune checkpoint inhibitors (ICI) in patients with hepatitis C virus infection (HCV) has not been studied in many cancers as these patients were excluded from most ICI trials. This poses a degree of uncertainty when an HCV patient […]
Read More